Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Quest Diagnostics Q3 2026 Results: Net Income $312M, Up 27.3% YoY

Quest Diagnostics reported net revenues of $3,097 million for the third quarter of 2026, an increase from $2,816 million in the prior year. Net income attributable to the company rose to $312 million, driven by higher operating income and lower interest expenses compared to the same period in 2025.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue3,097.02,816.0
Profit before tax416.0328.0
Net income312.0245.0
EPS (diluted, $ a share)$2.78$2.16

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+27.3%
Revenue, year on year+10.0%
Operating margin15.5%
Source

10-Q filed with the SEC, NYSE: DGX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Quest Diagnostics Inc: key numbers

Share price
$262.21Close, Nov 16
Market cap
$28.8B
Shares outstanding
110.02MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Quest Diagnostics Inc

All →
7:14 PM ET Form 4
Insider Selling

Quest Diagnostics SVP for Diagnostic Services Patrick Plewman Sells $3.02M of Stock

Patrick Plewman, SVP for Diagnostic Services, sold 11,717 shares of Quest Diagnostics Inc at $257.34 a share, worth $3.02M in total on Nov 9, 2026. Shares held after the trade: 14,684 (-4.2%).

Value
$3.02M
Shares
11,717
Average price
$257.34
Role
SVP for Diagnostic Services
Holding change
-4.2%
Trade date
Nov 9, 2026
7:05 PM ET Form 4
Insider Selling

Quest Diagnostics EVP Catherine T. Doherty Sells $5.48M of Stock

Catherine T. Doherty, EVP, sold 22,105 shares of Quest Diagnostics Inc at $245.45 to $251.24 a share (average $248.02) in 7 transactions, worth $5.48M in total on Nov 3, 2026. Shares held after the trade: 71,949 (-3.9%).

Value
$5.48M
Shares
22,105
Average price
$248.02
Role
EVP
Holding change
-3.9%
Trade date
Nov 3, 2026
6:06 PM ET Form 4
Insider Selling

Quest Diagnostics Insider Gary M. Pfeiffer Sells $292K of Stock

Gary M. Pfeiffer sold 1,203 shares of Quest Diagnostics Inc at $243.00 a share, worth $292K in total on Oct 26, 2026. Shares held after the trade: 29,802 (-3.9%).

Value
$292K
Shares
1,203
Price
$243.00
Holding change
-3.9%
Trade date
Oct 26, 2026
6:54 AM ET 8-K
Cybersecurity Incident

Quest Diagnostics Cybersecurity Incident

Quest Diagnostics disclosed a cybersecurity incident involving unauthorized access to its Quanum LSM system, which clients use for test orders and results. The company believes an unauthorized party accessed certain patient records and has notified federal law enforcement. The incident has not materially disrupted business operations or the company's ability to serve patients.

6:50 AM ET 8-K
Financial Results

Quest Diagnostics Financial Results

Quest Diagnostics reported third quarter 2026 revenues of $3.10 billion, a 10% increase year-over-year driven by strong organic growth across physician, hospital, and consumer channels. The company raised its full-year 2026 guidance for both revenue and EPS, citing productivity gains from automation and AI and expanding clinical care needs.

Term
Q3 2026

“We delivered revenue growth of 10% and adjusted EPS growth of over 15% on continued strength across our physician, hospital and consumer channels, complemented by productivity gains from automation and AI. Our robust organic revenue growth demonstrates that our solutions are fulfilling the expanding clinical care needs of an aging population as well as the increasing number of people focused on prevention and wellness. With these growth trends and our strong performance, we are raising our revenue and EPS guidance for the full year.”

Jim Davis, Chairman, CEO and President
4:31 PM ET 8-K
Leadership Change

Quest Diagnostics Leadership Change

Quest Diagnostics announced that Catherine T. Doherty will retire in July 2027, transitioning to a new role as Executive Vice President effective November 1, 2026. In her new role, she will oversee health systems, a joint venture with Corewell Health, and the Project Nova modernization initiative while maintaining her current base salary and receiving a $1.2 million RSU grant.

Term
through July 2027

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.